𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia

✍ Scribed by Sarah A. Holstein; John B. Stokes; Raymond J. Hohl


Book ID
104040807
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
88 KB
Volume
33
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Second-generation tyrosine kinase inhibi
✍ Ayalew Tefferi πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 86 KB

Imatinib should continue to be the front‐line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second‐generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.